4-AcO-DiPT Stats & Data

4-AcO-DiPT was first characterized in the scientific literature by Alexander Shulgin, with documentation appearing by 2003. The compound is described in TiHKAL (Tryptamines I Have Known and Loved), Shulgin's comprehensive reference work on tryptamine compounds co-authored with Ann Shulgin. The substance represents one of the early psychedelic research chemicals that emerged following Shulgin's initial synthesis and documentation, predating the widespread proliferation of online research chemical vendors that would later characterize the early 2000s market. It was first identified as a novel designer drug in 2005, marking its appearance in recreational and research contexts outside of Shulgin's laboratory work.

Forked from Subjective Effect Documentation work by Josie Kins, August 2016. Via dose.wiki (CC0).

The toxicity and long-term health effects of recreational 4-AcO-DiPT use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because 4-AcO-DiPT is a research chemical with very little history of human usage. Anecdotal evidence from people within the psychonaut community who have tried 4-AcO-DiPT suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (although nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption. It is strongly recommended that one use harm reduction practices when using this drug.

Effects aggregated from 32 experience reports (32 single-substance Erowid)

Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

Also reported in combinations. In the 15 4-AcO-DiPT reports where another drug was taken too, 4 mention hospital, emergency services or an overdose, 1 a seizure and 0 psychosis (too few reports for percentages). In the 32 single-substance reports: 9.4%, 0.0% and 0.0%. These are not in the figures above: they cannot be put down to 4-AcO-DiPT alone, and a mention is not always something that happened to the writer.

How effect frequency changes across dose levels. Whiskers, and the numbers' hover text, give each figure's 95% interval.

Not drawn, too few reports (a dose tier needs 20): Oral Strong (n=16). Why 20?

Dose distribution from experience reports, one dose per report (the first listed). Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route: most are real heavy doses or overdoses, not mistakes.

From 70 of 74 recorded dose entries: those that state a weight (mg, g or µg), in routes with at least five of them. Values above Q3 + 3×IQR, far above what people typically take, are left out; they can include real heavy doses and overdoses, not only mistakes.

Most co-occurring substances, as a share of all 47 reports filed under 4-AcO-DiPT; whiskers are 95% intervals

Most common forms and preparations, as a share of the 39 reports that give one; whiskers are 95% intervals

Dose per kg of body weight, one dose per report (the first listed), from reports giving a weight of 30–250 kg. Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route.

Redosing behavior across 39 reports